Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2024 | YoY |
|---|---|---|
| Revenue | 7m | 145.79% |
| Gross profit | -23.56m | 23.93% |
| Net profit | -51.4m | 4.58% |
| EBITDA | -49.8m | 1.29% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €6.36m |
Number of shares | 64.25m |
52-week high/low | €1.51 - €0.085 |
| Dividends | No |
Beta | 1.02 |
P/E ratio | -0.04 |
PEG ratio | 0.00 |
P/B ratio | -0.04 |
P/S ratio | 0.91 |
Company profile
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It The company was founded in 2008 and is headquartered in Vélizy-Villacoublay, France.
| Name | Carmat |
| CEO | Stephane Piat |
| Headquarters | Vélizy-Villacoublay,
France |
| Website | |
| IPO | 13/07/2010 |
| Employees | 162 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Euronext | ALCAR.PA |
Pnk | CKMTF |
Frankfurt | CXT.F |
Düsseldorf | CXT.DU |
Paris | ALCAR.PA |
München | CXT.MU |
